WebOct 13, 2024 · Rekambys is a type of HIV medicine called a non-nucleoside reverse transcriptase inhibitor (NNRTI). It blocks the activity of reverse transcriptase, an enzyme … WebJan 5, 2024 · 2.1 Cabotegravir (Vocabria, Viiv Healthcare) with rilpivirine (Rekambys, Janssen) is indicated 'for the treatment of HIV‑1 infection in adults who are virologically suppressed (HIV‑1 RNA fewer than 50 copies/ml) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents …
Rekambys Doc History Medicines.ie
WebOct 19, 2024 · ICH GCP - EMA has recommended the granting of marketing authorisations for two new antiretroviral (ARV) medicines, Rekambys (rilpivirine) and Vocabria injection (cabotegravir). English Dansk Deutsch English Español Français Italiano Magyar Nederlands Norsk Polski Português Suomi Svenska Čeština Русский 日本語 简体中文 한국어 WebIndication. Vocabria injection is indicated, in combination with rilpivirine injection, for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior ... kc-103jndx 黒タグ
Media Centre ViiV Healthcare
WebREKAMBYS darf nicht angewendet werden, ... Fachpersonal bestimmt und sollten von den Ärzten und vom medizinischen Fachpersonal in Verbindung mit der Fachinformation … WebAdverse events should also be reported to GlaxoSmithKline on 0800 221 441. REKAMBYS (rilpivirine long acting injection), including the trademark is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned by the ViiV Healthcare group. PM-GB-CBR … WebMar 16, 2024 · Rekambys 900 mg prolonged-release suspension for injection - Patient Information Leaflet (PIL) by Janssen-Cilag Ltd kc-12 安全データシート